Movement Alert｜Abivax S.A. Falls 5.32% in Regular Trading, Phase 3 Trial Cancer Safety Concerns Continue to Weigh on Stock

Market Focus06-08

On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.

The decline reflects persistent investor anxiety over safety signals from the company's Phase 3 ABTECT maintenance trial for obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint with placebo-adjusted clinical remission rates of 39.3% (25mg) and 40.3% (50mg) at week 44 — described by the company as the highest placebo-adjusted remission rates in any UC maintenance Phase 3 study — the 50mg group reported cases of prostate cancer, breast cancer, colonic dysplasia, and multiple non-melanoma skin cancers.

The stock had previously plunged over 40% intraday on June 2 when the data was first released, before partially recovering. Wedbush Securities has noted that obefazimod faces elevated risk of a black box warning due to malignancy cases, while Jefferies analysts indicated the cancer-related adverse events will continue to suppress market sentiment and the drug's commercialization outlook. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117915223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117915223","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Falls 5.32% in Regular Trading, Phase 3 Trial Cancer Safety Concerns Continue to Weigh on Stock","media":"Market Focus","content":"<p><p>On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.</p><p>The decline reflects persistent investor anxiety over safety signals from the company's Phase 3 ABTECT maintenance trial for obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint with placebo-adjusted clinical remission rates of 39.3% (25mg) and 40.3% (50mg) at week 44 — described by the company as the highest placebo-adjusted remission rates in any UC maintenance Phase 3 study — the 50mg group reported cases of prostate cancer, breast cancer, colonic dysplasia, and multiple non-melanoma skin cancers.</p><p>The stock had previously plunged over 40% intraday on June 2 when the data was first released, before partially recovering. Wedbush Securities has noted that obefazimod faces elevated risk of a black box warning due to malignancy cases, while Jefferies analysts indicated the cancer-related adverse events will continue to suppress market sentiment and the drug's commercialization outlook. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Falls 5.32% in Regular Trading, Phase 3 Trial Cancer Safety Concerns Continue to Weigh on Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Falls 5.32% in Regular Trading, Phase 3 Trial Cancer Safety Concerns Continue to Weigh on Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-08 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.</p><p>The decline reflects persistent investor anxiety over safety signals from the company's Phase 3 ABTECT maintenance trial for obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint with placebo-adjusted clinical remission rates of 39.3% (25mg) and 40.3% (50mg) at week 44 — described by the company as the highest placebo-adjusted remission rates in any UC maintenance Phase 3 study — the 50mg group reported cases of prostate cancer, breast cancer, colonic dysplasia, and multiple non-melanoma skin cancers.</p><p>The stock had previously plunged over 40% intraday on June 2 when the data was first released, before partially recovering. Wedbush Securities has noted that obefazimod faces elevated risk of a black box warning due to malignancy cases, while Jefferies analysts indicated the cancer-related adverse events will continue to suppress market sentiment and the drug's commercialization outlook. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1117915223","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117915223","pubTimestamp":1780927528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.The decline reflects persistent investor anxiety over safety...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"动向提示|Abivax S.A.常规交易下跌5.32%，3期试验癌症安全担忧继续打压股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On June 8, Abivax S.A. declined 5.32% in regular trading, trading at $97.13/share, with trading volume of approximately $54.04 million.The decline reflects persistent investor anxiety over safety signals from the company's Phase 3 ABTECT maintenance trial for obefazimod in moderately to severely active ulcerative colitis. While the trial met its primary endpoint with placebo-adjusted clinical remission rates of 39.3% (25mg) and 40.3% (50mg) at week 44 — described by the company as the highest placebo-adjusted remission rates in any UC maintenance Phase 3 study — the 50mg group reported cases of prostate cancer, breast cancer, colonic dysplasia, and multiple non-melanoma skin cancers.The stock had previously plunged over 40% intraday on June 2 when the data was first released, before partially recovering. Wedbush Securities has noted that obefazimod faces elevated risk of a black box warning due to malignancy cases, while Jefferies analysts indicated the cancer-related adverse events will continue to suppress market sentiment and the drug's commercialization outlook. Morgan Stanley lowered its price target from $145 to $132 while maintaining an overweight rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117915223","isCrawlerRequest":true}